Effectiveness and safety of isavuconazole prophylaxis for invasive fungal infections in the haematologic setting

• Published in: Hematology (Luxembourg) Vol. 27; no. 1; pp. 723 - 732
• Main Authors: Ping, Yang, Hongmei, Jing, Bellmann, Christian, Inês, Mónica, Macmillan, Tom, Webb, Neil, Aram, Jalal A., Penack, Olaf
• Format: Journal Article
• Language: English
• Published: England Taylor & Francis 01.12.2022; Taylor & Francis Group
• Subjects: Adult; antifungal agents; Antifungal Agents - adverse effects; azoles; haematologic malignancies; haematopoietic stem cell transplantation; Humans; Invasive fungal infections; Invasive Fungal Infections - drug therapy; Invasive Fungal Infections - etiology; Invasive Fungal Infections - prevention & control; Nitriles - therapeutic use; observational studies; preventive medicine; Pyridines; systematic review; Triazoles - adverse effects; antifungal agents; azoles; preventive medicine; observational studies; systematic review; haematologic malignancies; haematopoietic stem cell transplantation; Invasive fungal infections
• ISSN: 1607-8454; 1607-8454
• DOI: 10.1080/16078454.2022.2076046

Patients with haematologic malignancies are at high risk of developing invasive fungal infections (IFIs). Current guidelines recommend the use of azoles for IFI prophylaxis; however, in many clinical situations, antifungal prophylaxis is used off-label. We conducted a systematic literature review to provide haematologists with the available evidence on the effectiveness and safety of isavuconazole in IFI prophylaxis in interventional and real-world, observational studies. Embase, MEDLINE and Cochrane Library databases, and relevant conference proceedings and clinical trial registries, were searched for studies on the effectiveness and safety of isavuconazole prophylaxis in adults at high risk of IFIs. Studies were assessed for inclusion and risk of bias. Nine studies were eligible for inclusion in the review, eight of which were in haematologic populations (patients undergoing haematopoietic stem cell transplantation or with acute myeloid leukaemia or myelodysplastic syndromes; n = 5) or included haematologic populations (n = 3). Evidence from these studies suggests isavuconazole is effective for IFI prophylaxis in the haematologic setting. However, the studies frequently lacked safety data, most were based on small patient populations from single centres and risk of bias could not be assessed for five studies. These findings provide evidence for isavuconazole as an alternative azole for prophylaxis in high-risk populations. Limitations include lack of applicability of risk of bias assessment tools, level of filtering applied in the search strategy and focus on English-language publications. Isavuconazole may be an effective azole for IFI prophylaxis in high-risk haematologic populations, although further studies are needed.